Figure 3.

The profile of insulin treatment and its management before and after ceritinib administration. The day that ceritinib administration was started is defined as day 0. The fasting glucose levels and insulin therapy during ceritinib treatment are indicated. The fasting glucose levels were evaluated based on pre-breakfast self-measured blood glucose levels. The fasting glucose levels drastically increased after two weeks of ceritinib administration. After ceritinib discontinuation, the patient’s glucose levels rapidly declined, and the insulin dose was able to be reduced, despite continued prednisolone (PSL) treatment.